Plant Name: Diphylleia sinensis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.595E-12 | 3.102E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.436E-11 | 2.247E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOX4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 9.318E-11 | 2.536E-07 | ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, XDH |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.273E-10 | 2.771E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.922E-08 | 3.882E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOX4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.740E-08 | 5.870E-05 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 7.367E-07 | 4.456E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 9.570E-07 | 5.343E-04 | AR, CA2, CYP1A1, CYP1A2, ESRRA, FLT3, HSD17B2, TP53, TYR |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.519E-06 | 7.875E-04 | CA12, CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:1901700; response to oxygen-containing compound | 1.806E-06 | 9.144E-04 | AKR1B1, AR, CYP1A1, CYP1A2, CYP1B1, DAPK1, ESRRA, HSD17B2, NOX4, TP53, TYR |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 4.415E-06 | 1.962E-03 | ABCG2, CA12, CA2, CA7, HIF1A, HTT, NPSR1, TP53 |
| BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 5.768E-06 | 2.364E-03 | CYP1B1, HIF1A, NOX4, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.863E-06 | 2.364E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.863E-06 | 2.364E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.989E-06 | 2.624E-03 | CA2, CA7 |
| BP | GO:0032502; developmental process | GO:0048513; animal organ development | 7.317E-06 | 2.700E-03 | AR, CA2, CYP1A1, CYP1A2, ESRRA, FLT3, HIF1A, HSD17B2, HTT, TYR |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 8.227E-06 | 2.958E-03 | ALOX15, CA2, CYP1A1, CYP1A2, HIF1A, TP53 |
| BP | GO:0009987; cellular process | GO:0034599; cellular response to oxidative stress | 1.128E-05 | 3.559E-03 | AKR1B1, CYP1B1, DAPK1, NOX4, TP53 |
| BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 1.292E-05 | 3.906E-03 | ABCC1, AKR1B1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.396E-05 | 4.001E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.396E-05 | 4.001E-03 | CYP1A2, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.476E-05 | 4.173E-03 | ABCC1, ALOX15, ALOX5 |
| BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 1.878E-05 | 5.076E-03 | AR, DAPK1, HTT, LMNA |
| BP | GO:0008283; cell proliferation | GO:0042127; regulation of cell proliferation | 1.890E-05 | 5.076E-03 | AHR, AKR1B1, AR, CYP1B1, ESRRA, FLT3, HIF1A, LMNA, NOX4, TP53, XDH |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.958E-05 | 5.076E-03 | CYP1A1, CYP2C19, CYP2C9 |
| BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 2.047E-05 | 5.243E-03 | ABCG2, CA2, CA7, HIF1A, HTT, NPSR1, TP53 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 2.264E-05 | 5.667E-03 | AKR1B1, CYP1A2, NOX4, XDH |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.332E-05 | 5.761E-03 | CA12, CA2, CA7 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.355E-05 | 5.761E-03 | CA2, CA7, HIF1A, HTT, NPSR1 |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 3.484E-05 | 8.247E-03 | ALOX15, ALOX5 |
| BP | GO:0008152; metabolic process | GO:1901615; organic hydroxy compound metabolic process | 3.589E-05 | 8.402E-03 | AKR1B1, ALOX15, CYP1A1, CYP1B1, HIF1A, TYR |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.289E-05 | 9.831E-03 | CA12, CA2, CA7 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.081E-08 | 8.323E-07 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.318E-08 | 8.925E-07 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 9.019E-07 | 1.389E-05 | CYP2C9; HSD17B1; ALOX5; HSD17B2; CYP1A2; ALOX15; CYP1A1; AKR1B1; CYP2C19; TYR; XDH |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 9.516E-08 | 2.442E-06 | CYP2C9; CYP1A2; ALOX15; CYP2C19 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.346E-07 | 2.592E-06 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP2C19 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.159E-06 | 2.375E-05 | CYP2C9; ALOX5; ALOX15; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.165E-06 | 4.009E-05 | CYP2C9; CYP1A2; CYP1A1; CYP1B1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.282E-05 | 1.757E-04 | CYP2C9; ALOX5; ALOX15; CYP2C19 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 2.898E-05 | 2.029E-04 | CYP1A2; CYP1A1; CYP1B1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.844E-04 | 1.460E-03 | AR; FLT3; DAPK1; HIF1A; TP53 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.367E-04 | 8.099E-04 | FLT3; TP53; HIF1A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.249E-04 | 8.017E-04 | CYP2C9; CYP1A2; CYP1A1 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.042E-06 | 2.375E-05 | CA12; CA2; CA7 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.493E-04 | 8.209E-04 | CYP2C9; CYP1A2; CYP2C19 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.720E-03 | 8.277E-03 | DAPK1; TP53 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 7.855E-03 | 3.183E-02 | AR; TP53 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 9.785E-03 | 3.767E-02 | ABCC1; CYP1B1; TP53 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 5.069E-03 | 2.168E-02 | CA2; ABCG2 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.979E-03 | 8.962E-03 | ABCC1; ABCG2 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.348E-02 | 4.871E-02 | TP53; HIF1A |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.392E-02 | 4.871E-02 | ABCC1; TP53 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.169E-05 | 1.757E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| C00-D49: Neoplasms | Melanoma | C43 | TYR |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR |
| NA: NA | Male hypogonadism | NA | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; ESRRA |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR |
| NA: NA | HIV infections | NA | AHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; HIF1A; TP53; FLT3; FLT3 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; ABCC1; ESRRA |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; ESRRA |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| NA: NA | GIST | NA | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; FLT3; FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; FLT3 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; ABCC1; ABCC1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; TYR; AKR1B1; ESRRA |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |